Alzheimer Disease/Dementia

US adults want to know early on if they have Alzheimer disease, when treatment may slow it, and they are willing to participate in trials of new drugs.

Biomarkers in a pattern characteristic of Alzheimer pathology were identified in unspecified dementia, Parkinson dementia, and frontotemporal dementia.

Authors found a dose-response relationship between MetS and dementia onset in the 4th decade; in those with all 5 components, risk of dementia was increased by 77%.

The findings suggest that women who experience early menopause (age <40 vs >50 years) may constitute a sex-specific high-risk group for cognitive decline.

Interventions to protect or improve auditory health across the lifespan could be a cost-effective means of slowing the rapid rise of dementia in the US, authors wrote.

Adults with a cannabis-related acute care visit or hospitalization were at 23% and 72% greater risk of a new dementia diagnosis within 5 years, a new study finds.

Your daily dose of the clinical news you may have missed.

In addition to support for phase 3 CLARITY AD findings, new evidence was presented supporting lecanemab safety and efficacy in ApoE ε4 carriers and non-carriers.

Using the proprietary Roche Brainshuttle technology, trontinemab leads to deep, rapid amyloid plaque reduction with a favorable safety profile.

Your daily dose of the clinical news you may have missed.

Data on use of lecanemab in real world clinical settings will come from a neurologic case series review and a retrospective chart review of long-term use, both in early AD.

In a small study of adults genetically predisposed to early-onset dementia, anti-amyloid treatment to remove plaque reduced risk of developing symptoms by 50%.

Higher levels of cardiovascular health were associated with lower levels of neurofilament light chain across age, sex, race/ethnicity, and Alzheimer disease risk.

Analysis of data from the donanemab TRAILBLAZER development program underscores the essential role of patient selection and treatment monitoring.

Axsome Therapeutics reported that the FDA feedback supports the company's regulatory package for a sNDA for the dextromethorphan/bupropion combination.

The proprietary combination of 2 neurostimulation modalities deployed simultaneously may enhance efficacy while reducing treatment time by 70%, the company said.

Phospho-tau serine-262 and serine-356 were identified as biomarkers for early Alzheimer disease detection in a new study published in Nature Medicine.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.

Georgetown University memory disorders expert R Scott Turner, PhD, MD, reviews the science behind approval of lecanemab for monthly maintenance dosing of lecanemab.